South Australian Neonatal Medication Guidelines

Vitamin E

104.7mg/mL oral mixture

© Department of Health and Wellbeing, Government of South Australia. All rights reserved

Note

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

• The use of interpreter services where necessary,
• Advising consumers of their choice and ensuring informed consent is obtained,
• Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
• Documenting all care in accordance with mandatory and local requirements

Synonyms

d-alpha-tocopherol acetate

d-alpha-tocopherol

Note

Vitamin E liquid (Micel E Pretorius®) contain 104.7 mg/mL of d-alpha-tocopherol acetate (equivalent to 156 international units of d-alpha-tocopherol acetate).

Dose and Indications

For prevention of Vitamin E deficiency in preterm infants < 2000g at birth or < 34 weeks gestation where nutritional intake is inadequate (e.g., in preterm neonates receiving unfortified breast milk or term/modified term formula)

Oral

10.5 mg (0.1 mL) ONCE daily

To be commenced when tolerating enteral feeds of 150 mL/kg daily.

Continue until term corrected age OR until discharge if this is earlier.

For treatment of oxidative haemolysis in preterm neonates

**Oral**

21 mg (0.2 mL) ONCE daily

**Chronic Cholestasis**

**Oral**

42 mg (0.4 mL) ONCE daily

To be commenced when tolerating enteral feeds of 150 mL/kg daily.

Continue until conjugated bilirubin normalises

**Preparation and Administration**

**Oral**

Oral mixture contains 104.7 mg/mL

<table>
<thead>
<tr>
<th>Dose</th>
<th>10.5 mg</th>
<th>21 mg</th>
<th>42 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.1 mL</td>
<td>0.2 mL</td>
<td>0.4 mL</td>
</tr>
</tbody>
</table>

Give with feeds to reduce gastrointestinal irritation

**Adverse Effects**

Feeding intolerance may occur due to hyperosmolarity of preparation.

**Monitoring**

> Assess feeding tolerance

**Practice Points**

> Can dilute with sterile water or formula to reduce the osmolarity

> 1 mg d-alpha-tocopherol acetate = 1.5 international units of vitamin E
### Document Ownership & History

**Developed by:** SA Maternal, Neonatal & Gynaecology Community of Practice  
**Contact:** Health.NeoMed@sa.gov.au  
**Endorsed by:** Commissioning and Performance, SA Health  
**Next review due:** 23/11/2027  
**ISBN number:** 978-1-76083-542-2  
**CGSQ reference:** NMG041

**Policy history:**
- Is this a new policy (V1)? **N**
- Does this policy amend or update an existing policy? **Y**
  - If so, which version? **V2.0**
- Does this policy replace another policy with a different title? **N**
  - If so, which policy (title)?

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>23/11/2022</td>
<td>V3</td>
<td>Domain Custodian, Clinical Governance, Safety and Quality</td>
<td>Full review in line with 5-year scheduled timeline review.</td>
</tr>
<tr>
<td>11/08/2017</td>
<td>V2</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Change in formulation</td>
</tr>
</tbody>
</table>